Phibro Animal Health's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Phibro Animal Health in the fourth quarter 2026?
Phibro Animal Health Corporation achieved a return on average equity (ROE) of 29.66 % in its fourth quarter 2026, which is below Phibro Animal Health's average return on equity, which stands at 51.35%.

ROE decreased relative to the period ending , due to the decline in net income.

Within the Major Pharmaceutical Preparations industry 27 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 392, from total ROE ranking in the third quarter 2026 at 398.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Equity Change	34.93 %	36.03 %	11.32 %	20.56 %	-
Y / Y Net Income Change	26.05 %	15.06 %	762.14 %	280.32 %	2190.43 %
Net Income (TTM) in Millions	100	95	92	68	48
Return On Equity (TTM)	29.66 %	30.6 %	32.06 %	24.22 %	18.1 %
PAHC's Total Ranking	# 392	# 398	# 495	# 709	# 1093
Equity (TTM) in Millions	385	362	286	312	286
Seq. Equity Change	6.54 %	26.65 %	-8.34 %	9.1 %	7.4 %
Seq. Net Income Change	-9.63 %	-12.51 %	3.51 %	54.01 %	-17.51 %

Back to PAHC Management Effectiveness >> PAHC's 5 Years Annual ROE >> Compare PAHC ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 28
Sector	# 58
Overall	# 392

Return On Equity Statistics
High	Average	Low
269.1 %	51.35 %	0.89 %
(Dec 31 2015)		(Jun 30 2024)

PAHC Annual Return On Equity	(Jun 30 2026) 2026	(Jun 30 2025) 2025	(Jun 30 2024) 2024	(Jun 30 2023) 2023	(Jun 30 2022) 2022
Total Equity in Millions	385	286	257	283	262
Y / Y Equity Change	34.93 %	11.32 %	-9.16 %	7.65 %	10.03 %
Net Income in Millions	100	48	2	33	49
Y / Y Net Income Change	106.61 %	1897.68 %	-92.59 %	-33.69 %	-9.58 %
Return On Equity	25.87 %	16.89 %	0.94 %	11.54 %	18.74 %

Back to PAHC Management Effectiveness >> PAHC's 5 Years Annual ROE >> Compare PAHC ROE to its Competitors

Annual Roe Comment

In 2026 ROE improved to 25.87 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PAHC's' Return on Equity at Yahoo Finance
PAHC's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PAHC's Competitors
Subscribers only: Roe for Phibro Animal Health's Suppliers
Subscribers only: Return On Equity for PAHC's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Q32 Bio Inc	76.88 %
3m Company	76.55 %
Oramed Pharmaceuticals Inc	73.03 %
Tg Therapeutics Inc	72.30 %
Idexx Laboratories Inc	71.96 %
Elite Pharmaceuticals Inc	71.10 %
Zoetis Inc	68.87 %
Rallybio Corporation	68.56 %
Earth Science Tech Inc	66.17 %
Aurinia Pharmaceuticals Inc	59.00 %
Vaxart Inc	53.04 %
Qhslab Inc	51.21 %
Tenet Healthcare Corp	50.64 %
Nrc Health	48.29 %
Concentra Group Holdings Parent Inc	48.13 %
Bristol myers Squibb Company	46.65 %
Agilent Technologies inc	41.99 %
Eton Pharmaceuticals Inc	40.13 %
Adma Biologics Inc	39.59 %
Dexcom Inc	36.25 %
Transmedics Group Inc	33.37 %
Arcutis Biotherapeutics Inc	32.92 %
Caredx Inc	32.81 %
Zevra Therapeutics Inc	32.56 %
Acadia Pharmaceuticals Inc	32.39 %
Pro dex Inc	31.96 %
Protalix Biotherapeutics inc	31.61 %
Illumina Inc	31.08 %
Innoviva Inc	30.03 %
Phibro Animal Health Corporation	29.66 %

Date modified: 2026-09-08T15:22:21+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.